Scholars Central

Conference abstractPublished 15 Apr 2013

Treatment options of uveitis, current standards and what's coming

Authors: David S Chu

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Uveitis is an ocular condition characterized by the presence of inflammation in the eye. It affects 1 in 1000 people in the United States and the disease is usually manifestation of autoimmune etiology. It can affect patients of all ages, however, it is more common in young adults. Uveitis and its complication are some of the leading causes of blindness in the US. Despite its impact to the society, treatment of uveitis remains heterogeneous. There is a general consensus among specialists, but there is no preferred practice pattern in place. Furthermore, there are very few options for treatment of chronic uveitis that has FDA indication. In fact, chronic use of oral corticosteroids is the only FDA approved therapy, however, such therapy carries significant morbidity to the patient. There are numerous FDA trials that are ongoing to evaluate various steroid sparing options, such as existing drug on the market and novel agents, as well as alternative method of delivery, including iontophoresis. Through these trials, we hope to develop treatment patterns that are effective and safe for patients with uveitis.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical and Experimental Ophthalmology.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical and Experimental Ophthalmology
  • SubjectOphthalmology & Optometry
  • BylineArticles whose byline prints “David S Chu”